<p>/PRNewswire/ -- 中国医科大学附属医院（CMUH）在院长卓德扬博士的领导下，宣布在外泌体药物递送方面取得重大突破，此项成就与永盛生物科技和闪耀生物医学合作完成。在之前成功开发针对实体肿瘤的 HLA-G 靶向外泌体的基础上，研究团队现在将这一先进平台扩展到中央神经系统（CNS）这一高度挑战的领域。</p>
<p>继续阅读</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null"/></p>
<p>由中国医科大学附属医院院长卓德扬博士领导的研究团队，与永盛生物科技和闪耀生物科技合作，共同推出了全球首个主动导航的αDAT-EV 脑靶向外泌体平台。（从左到右：闪耀生物科技副总经理李铭娟先生；中央研究院林长庚院士；中国医科大学附属医院院长卓德扬博士。）</p>
<p>这一成果是全球首个主动导航的脑靶向外泌体平台——αDAT-EV，能够跨越血脑屏障（BBB）运输治疗药物，并精确导向与帕金森病（PD）相关的受影响神经区域。这项具有里程碑意义的研究已发表在国际领先的期刊《纳米生物技术杂志》上。</p>
<p><strong>αDAT-EV：全球首个主动导航的脑靶向外泌体药物递送平台</strong></p>
<p>卓博士指出，随着全球人口老龄化，神经退行性疾病如帕金森病的发病率持续急剧上升。然而，几十年来，神经治疗药物面临着一个巨大的障碍：近 98% 的药物无法有效穿越血脑屏障，严重限制了治疗效果，并减缓了神经医学的进展。</p>
<p>为了克服这一瓶颈，CMUH 的研究人员与闪耀生物科技合作，采用基因工程技术修改外泌体表面的抗体片段，以识别多巴胺转运蛋白（DAT）。这一创新使得αDAT-EV 能够主动识别和靶向多巴胺能神经元——有效地为治疗药物配备了类似 GPS 的导航系统，指导其到达病变脑区，同时提高小分子药物的生物利用度。</p>
<p><strong>纳米级</strong> <strong>“</strong> <strong>药物指南</strong> <strong>”：用现代生物技术重新构想姜黄素</strong></p>
<p>中央研究院林长庚院士解释说，姜黄素在传统医学中被誉为 “食药同源”，以其抗氧化和抗炎特性而闻名。现代研究已证实其能够修复神经损伤并清除病理性蛋白聚集物。尽管前景广阔，但姜黄素的益处历史上一直是 “可见但无法获得”：水溶性差、代谢迅速以及无法穿越血脑屏障导致其在临床环境中的脑浓度微乎其微。</p>
<p>通过αDAT-EV 脑靶向平台，姜黄素现在可以被主动引导进入大脑，作为现代纳米级药物指南。这一突破体现了传统医学智慧与尖端生物技术的结合，并成为传统医学科学现代化的有力模型。</p>
<p><strong>多途径细胞修复展示强大的转化潜力</strong></p>
<p>闪耀生物科技副总经理李铭娟先生表示，使用装载姜黄素的αDAT-EV 进行的临床前研究在细胞和动物模型中显示出良好的治疗效果，突显了该平台作为下一代纳米药物载体的潜力：</p>
<p><strong>1. 精确靶向</strong></p>
<p>该平台显著增强了药物穿透血脑屏障的能力，并在与帕金森病相关的关键区域（包括黑质和腹侧被盖区）中富集治疗药物。</p>
<p><strong>2. 激活修复机制</strong></p>
<p>αDAT-EV 触发细胞自噬 - 溶酶体途径和线粒体修复机制，有效清除病理性α-突触核蛋白聚集物，缓解疾病症状。</p>
<p><strong>3. 免疫调节</strong></p>
<p>该治疗促进了大脑小胶质细胞从促炎表型向修复表型的转变，表明神经炎症减少。</p>
<p><strong>4. 改善运动功能</strong></p>
<p>帕金森病动物模型在运动协调方面表现出显著恢复，突显了该平台强大的临床转化潜力。</p>
<p><strong>一个多功能的外泌体平台扩展 CNS 治疗前沿</strong></p>
<p>αDAT-EV 脑靶向外泌体平台具有高度的可扩展性和扩展性。虽然最初开发用于递送针对癌细胞的细胞毒性药物，但现在展示了运输神经修复治疗药物的能力。</p>
<p>这一创新为长期受血脑屏障限制的神经退行性疾病提供了变革性解决方案。展望未来，该平台可能被调整用于递送小分子药物、核酸疗法（mRNA）或基于蛋白质的治疗药物，潜在应用于阿尔茨海默病、中风及其他 CNS 疾病，显著推动神经学和精准医学领域的发展。</p>
<p>在 2025 年第四季度，永盛生物科技宣布通过股份交换交易收购闪耀生物科技 100% 的股权，导致闪耀生物科技成为全资子公司。股份交换的生效日期为 2026 年 1 月 13 日。总经理黄文良先生表示，此次收购在两家公司技术平台和治疗重点领域之间创造了强大的协同效应，加速了细胞治疗向符合台湾再生医学法和再生医学产品法的国际竞争制药行业的推进。</p>
<p>根据台湾的再生医学双重行动框架，自 2026 年 1 月 1 日起，针对危及生命或严重致残疾病的再生产品可在完成 II 期临床试验并证明安全性和初步疗效后申请有条件的五年市场授权。此途径显著加速了商业化进程，并为全球老龄化社会提供了更好的治疗选择。</p>
<p>注 1：Shine Out Biotechnology 致力于开发下一代外泌体药物递送平台。通过利用专有的基因工程和制造技术，该公司解决了外泌体产量和靶向特异性方面的长期挑战。Shine-On 以 “精准递送和再生修复” 为核心，旨在成为全球外泌体基础治疗的领导者。</p>
<p>注 2：纳米生物技术杂志。</p>
<p>来源：中国医科大学附属医院</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTI4Jk5ld3NJdGVtSWQ9SEs3MzEyNiZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMjgwNzQzUFJfTkVXU19VU1BSX19fX19ISzczMTI2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTI4Jk5ld3NJdGVtSWQ9SEs3MzEyNiZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMjgwNzQzUFJfTkVXU19VU1BSX19fX19ISzczMTI2"/></p>

<p>中国医科大学附属医院（CMUH）宣布在基于外泌体的帕金森病药物递送方面取得突破，与永盛生物科技和闪耀生物医学合作。他们开发了αDAT-EV 平台，该平台能够跨越血脑屏障运输治疗药物，针对受影响的神经区域。这一创新使得以神曲素为代表的神经保护剂能够有效送达大脑。前临床研究显示，在增强药物渗透、激活修复机制和改善动物模型的运动功能方面取得了良好结果。该平台在各种中枢神经系统疾病中具有潜在应用，并可扩展用于未来的治疗</p>

<p>, /PRNewswire/ -- China Medical University Hospital (CMUH), under the leadership of Superintendent Dr. Cho Der-Yang, announced a major breakthrough in exosome-based drug delivery, achieved in collaboration with Ever Supreme Bio Technology and Shine-On Biomedical. Building on their prior success in developing HLA-G–targeted exosomes for solid tumors, the research team has now extended this advanced platform into the highly challenging domain of the central nervous system (CNS).</p>
<div class="lb-trans"><p>/PRNewswire/ -- 中国医科大学附属医院（CMUH）在院长卓德扬博士的领导下，宣布在外泌体药物递送方面取得重大突破，此项成就与永盛生物科技和闪耀生物医学合作完成。在之前成功开发针对实体肿瘤的 HLA-G 靶向外泌体的基础上，研究团队现在将这一先进平台扩展到中央神经系统（CNS）这一高度挑战的领域。</p>
</div><p>Continue Reading</p>
<div class="lb-trans"><p>继续阅读</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null" alt="" original-src="https://www.prnewswire.com/news-releases/null"/></p>
<p>The research team led by Dr. Cho Der-Yang, Superintendent of China Medical University Hospital, in collaboration with Ever Supreme Bio Technology and Shine Out Biotechnology, jointly unveiled the world’s first actively navigated αDAT-EV Brain-Targeting Exosome Platform. (From left to right: Mr. Lee Ming-Juan, Vice General Manager of Shine Out Bio Technology; Academician Dr. LIN Jaung-Geng of Academia Sinica; Dr. Cho Der-Yang, Superintendent of China Medical University Hospital.)</p>
<div class="lb-trans"><p>由中国医科大学附属医院院长卓德扬博士领导的研究团队，与永盛生物科技和闪耀生物科技合作，共同推出了全球首个主动导航的αDAT-EV 脑靶向外泌体平台。（从左到右：闪耀生物科技副总经理李铭娟先生；中央研究院林长庚院士；中国医科大学附属医院院长卓德扬博士。）</p>
</div><p>The result is a world-first, actively navigated brain-targeting exosome platform—αDAT-EV—capable of transporting therapeutic agents across the blood–brain barrier (BBB) and precisely directing them to impacted neural regions implicated in Parkinson's disease (PD). This landmark research has been published in the leading international publication Journal of Nanobiotechnology.</p>
<div class="lb-trans"><p>这一成果是全球首个主动导航的脑靶向外泌体平台——αDAT-EV，能够跨越血脑屏障（BBB）运输治疗药物，并精确导向与帕金森病（PD）相关的受影响神经区域。这项具有里程碑意义的研究已发表在国际领先的期刊《纳米生物技术杂志》上。</p>
</div><p><strong>αDAT-EV: The World's First Actively Navigated Brain-Targeting Exosome Drug Delivery Platform</strong></p>
<div class="lb-trans"><p><strong>αDAT-EV：全球首个主动导航的脑靶向外泌体药物递送平台</strong></p>
</div><p>Dr. Cho noted that as global populations age, the prevalence of neurodegenerative diseases such as Parkinson's disease continues to rise sharply. Yet for decades, neurological therapeutics have faced a formidable obstacle: nearly 98% of drugs fail to effectively cross the blood–brain barrier, severely limiting treatment efficacy and slowing progress in neurological medicine.</p>
<div class="lb-trans"><p>卓博士指出，随着全球人口老龄化，神经退行性疾病如帕金森病的发病率持续急剧上升。然而，几十年来，神经治疗药物面临着一个巨大的障碍：近 98% 的药物无法有效穿越血脑屏障，严重限制了治疗效果，并减缓了神经医学的进展。</p>
</div><p>To overcome this bottleneck, CMUH researchers, together with Shine Out Bio Technology, employed genetic engineering techniques to modify antibody fragments on the surface of exosomes that recognize the dopamine transporter (DAT). This innovation enables αDAT-EVs to actively identify and target dopaminergic neurons—effectively equipping therapeutic agents with a GPS-like navigation system that directs them to diseased brain regions while improving the bioavailability of small-molecule drugs.</p>
<div class="lb-trans"><p>为了克服这一瓶颈，CMUH 的研究人员与闪耀生物科技合作，采用基因工程技术修改外泌体表面的抗体片段，以识别多巴胺转运蛋白（DAT）。这一创新使得αDAT-EV 能够主动识别和靶向多巴胺能神经元——有效地为治疗药物配备了类似 GPS 的导航系统，指导其到达病变脑区，同时提高小分子药物的生物利用度。</p>
</div><p><strong>A Nano-Scale</strong> <strong>&#34;</strong> <strong>Medicinal Guide</strong> <strong>&#34;: Reimagining Curcumin with Modern Biotechnology</strong></p>
<div class="lb-trans"><p><strong>纳米级</strong> <strong>“</strong> <strong>药物指南</strong> <strong>”：用现代生物技术重新构想姜黄素</strong></p>
</div><p>Academician Dr. Lin Jaung-Geng of Academia Sinica explained that curcumin, long revered in traditional medicine as a &#34;food-medicine homolog,&#34; is known for its antioxidant and anti-inflammatory properties. Modern research has confirmed its ability to repair neuronal damage at the source and clear pathological protein aggregates. Despite its promise, the benefits of curcumin have historically been &#34;visible but unattainable&#34;: poor water solubility, rapid metabolism, and inability to cross the blood–brain barrier have resulted in negligible brain concentrations in clinical settings.</p>
<div class="lb-trans"><p>中央研究院林长庚院士解释说，姜黄素在传统医学中被誉为 “食药同源”，以其抗氧化和抗炎特性而闻名。现代研究已证实其能够修复神经损伤并清除病理性蛋白聚集物。尽管前景广阔，但姜黄素的益处历史上一直是 “可见但无法获得”：水溶性差、代谢迅速以及无法穿越血脑屏障导致其在临床环境中的脑浓度微乎其微。</p>
</div><p>Through the αDAT-EV brain-targeting platform, curcumin can now be actively guided into the brain, functioning as a modern nano-scale medicinal guide. This breakthrough exemplifies the integration of traditional medical wisdom with cutting-edge biotechnology, and stands as a compelling model for the scientific modernization of traditional medicine.</p>
<div class="lb-trans"><p>通过αDAT-EV 脑靶向平台，姜黄素现在可以被主动引导进入大脑，作为现代纳米级药物指南。这一突破体现了传统医学智慧与尖端生物技术的结合，并成为传统医学科学现代化的有力模型。</p>
</div><p><strong>Multi-Pathway Cellular Repair Demonstrates Strong Translational Potential</strong></p>
<div class="lb-trans"><p><strong>多途径细胞修复展示强大的转化潜力</strong></p>
</div><p>According to Mr. Lee Ming-Juan, Vice General Manager of Shine Out Bio Technology, preclinical studies using αDAT-EVs loaded with curcumin have demonstrated promising therapeutic effects in both cellular and animal models, highlighting the platform's potential as a next-generation nano drug carrier:</p>
<div class="lb-trans"><p>闪耀生物科技副总经理李铭娟先生表示，使用装载姜黄素的αDAT-EV 进行的临床前研究在细胞和动物模型中显示出良好的治疗效果，突显了该平台作为下一代纳米药物载体的潜力：</p>
</div><p><strong>1. Precision Targeting</strong></p>
<div class="lb-trans"><p><strong>1. 精确靶向</strong></p>
</div><p>The platform significantly enhances drug penetration across the BBB and enriches therapeutic agents in key Parkinson's disease-related regions, including the substantia nigra and ventral tegmental area.</p>
<div class="lb-trans"><p>该平台显著增强了药物穿透血脑屏障的能力，并在与帕金森病相关的关键区域（包括黑质和腹侧被盖区）中富集治疗药物。</p>
</div><p><strong>2. Activation of Repair Mechanisms</strong></p>
<div class="lb-trans"><p><strong>2. 激活修复机制</strong></p>
</div><p>αDAT-EVs trigger cellular autophagy-lysosomal pathways and mitochondrial repair mechanisms, effectively clearing pathological α-synuclein aggregates and alleviating disease symptoms.</p>
<div class="lb-trans"><p>αDAT-EV 触发细胞自噬 - 溶酶体途径和线粒体修复机制，有效清除病理性α-突触核蛋白聚集物，缓解疾病症状。</p>
</div><p><strong>3.</strong> <strong>Immune Modulation</strong></p>
<div class="lb-trans"><p><strong>3. 免疫调节</strong></p>
</div><p>The treatment promotes a shift in brain microglia from a pro-inflammatory to a reparative phenotype, indicating reduced neuroinflammation.</p>
<div class="lb-trans"><p>该治疗促进了大脑小胶质细胞从促炎表型向修复表型的转变，表明神经炎症减少。</p>
</div><p><strong>4. Improved Motor Function</strong></p>
<div class="lb-trans"><p><strong>4. 改善运动功能</strong></p>
</div><p>Parkinson's disease animal models exhibited marked recovery in motor coordination, underscoring the platform's strong clinical translation potential.</p>
<div class="lb-trans"><p>帕金森病动物模型在运动协调方面表现出显著恢复，突显了该平台强大的临床转化潜力。</p>
</div><p><strong>A Versatile Exosome Platform Expanding the CNS Therapeutic Frontier</strong></p>
<div class="lb-trans"><p><strong>一个多功能的外泌体平台扩展 CNS 治疗前沿</strong></p>
</div><p>The αDAT-EV brain-targeting exosome platform is highly scalable and expandable. While initially developed to deliver cytotoxic payloads against cancer cells, it now demonstrates the ability to transport therapeutic agents for neuronal repair.</p>
<div class="lb-trans"><p>αDAT-EV 脑靶向外泌体平台具有高度的可扩展性和扩展性。虽然最初开发用于递送针对癌细胞的细胞毒性药物，但现在展示了运输神经修复治疗药物的能力。</p>
</div><p>This innovation offers a transformative solution for neurodegenerative diseases long constrained by the blood–brain barrier. Looking ahead, the platform may be adapted to deliver small-molecule drugs, nucleic acid therapies (mRNA), or protein-based therapeutics, with potential applications in Alzheimer's disease, stroke, and other CNS disorders, significantly advancing the fields of neurology and precision medicine.</p>
<div class="lb-trans"><p>这一创新为长期受血脑屏障限制的神经退行性疾病提供了变革性解决方案。展望未来，该平台可能被调整用于递送小分子药物、核酸疗法（mRNA）或基于蛋白质的治疗药物，潜在应用于阿尔茨海默病、中风及其他 CNS 疾病，显著推动神经学和精准医学领域的发展。</p>
</div><p>In the fourth quarter of 2025, Ever Supreme Bio Technology announced the acquisition of 100% equity in Shine Out Bio Technology through a share-exchange transaction, resulting in Shine Out becoming a wholly owned subsidiary. The effective date of the share swap is January 13, 2026. General Manager Mr. Huang Wen-Liang stated that the acquisition creates strong synergies between the two companies' technology platforms and therapeutic focus areas, accelerating the advancement of cell-based therapies into an internationally competitive pharmaceutical industry regulated under Taiwan's Regenerative Medicine Act and the Regenerative Medicine Products Act.</p>
<div class="lb-trans"><p>在 2025 年第四季度，永盛生物科技宣布通过股份交换交易收购闪耀生物科技 100% 的股权，导致闪耀生物科技成为全资子公司。股份交换的生效日期为 2026 年 1 月 13 日。总经理黄文良先生表示，此次收购在两家公司技术平台和治疗重点领域之间创造了强大的协同效应，加速了细胞治疗向符合台湾再生医学法和再生医学产品法的国际竞争制药行业的推进。</p>
</div><p>Under Taiwan's Regenerative Medicine Dual-Act framework, beginning January 1, 2026, regenerative products targeting life-threatening or severely disabling diseases may apply for a conditional five-year marketing authorization upon completion of Phase II clinical trials demonstrating safety and preliminary efficacy. This pathway significantly accelerates commercialization and promises improved therapeutic options for aging societies worldwide.</p>
<div class="lb-trans"><p>根据台湾的再生医学双重行动框架，自 2026 年 1 月 1 日起，针对危及生命或严重致残疾病的再生产品可在完成 II 期临床试验并证明安全性和初步疗效后申请有条件的五年市场授权。此途径显著加速了商业化进程，并为全球老龄化社会提供了更好的治疗选择。</p>
</div><p>Note 1: Shine Out Biotechnology is dedicated to developing next-generation exosome drug delivery platforms. Leveraging proprietary genetic engineering and manufacturing technologies, the company addresses longstanding challenges in exosome yield and targeting specificity. With &#34;precision delivery and regenerative repair&#34; at its core, Shine-On aims to become a global leader in exosome-based therapeutics.</p>
<div class="lb-trans"><p>注 1：Shine Out Biotechnology 致力于开发下一代外泌体药物递送平台。通过利用专有的基因工程和制造技术，该公司解决了外泌体产量和靶向特异性方面的长期挑战。Shine-On 以 “精准递送和再生修复” 为核心，旨在成为全球外泌体基础治疗的领导者。</p>
</div><p>Note 2: Journal of Nanobiotechnology.</p>
<div class="lb-trans"><p>注 2：纳米生物技术杂志。</p>
</div><p>SOURCE China Medical University Hospital</p>
<div class="lb-trans"><p>来源：中国医科大学附属医院</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTI4Jk5ld3NJdGVtSWQ9SEs3MzEyNiZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMjgwNzQzUFJfTkVXU19VU1BSX19fX19ISzczMTI2" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=HK73126&amp;Transmission_Id=202601280743PR_NEWS_USPR_____HK73126&amp;DateId=20260128"/></p>

07:43 ET
			
			
				CMUH-Ever Supreme Team Develops World-First Brain-Targeting Exosome Delivering Curcumin Across the Blood-Brain Barrier for Parkinson's Disease

prnewswire

华夏医药ETF

易方达沪深300医药ETF

纳斯达克生物科技指数 ETF - iShares Nasdaq

易方达恒生港股通创新药ETF

动态生物技术与基因组 ETF - Invesco

纽交所高增长板生物技术指数 ETF - First Trust

国泰中证生物医药ETF

华宝中证制药ETF

博时恒生港股通创新药精选ETF

创新药

博时恒生医疗保健(QDII-ETF)

美国制药 ETF - iShares

富国恒生港股通创新药及医疗保健ETF

招商中证生物科技主题ETF

易方达中证生物科技主题ETF

标普生物技术 ETF - SPDR

华夏上证科创板生物医药ETF

CMUH-Ever Supreme 团队开发了全球首个脑靶向外泌体技术，可以将姜黄素输送过血脑屏障，用于治疗帕金森病